ev3, Inc. (EVVV) news stock charts
ev3, Inc. (EVVV) Investment Summary:
ev3, Inc., a medical device company, focuses on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. It develops, manufactures, and markets a range of products that include stents, atherectomy and thrombectomy products, balloon angioplasty catheters, microcatheters and occlusion balloon systems, embolic protection devices, infusion catheters/wires, embolic coils, and liquid embolics. The company markets its products in the United States, Europe, and Canada through a direct sales force, and through distributors in the United States and international markets. ev3, Inc. has a research collaboration with Merck & Co., Inc. for the analysis of atherosclero...EV3 INC (EVVV:NASDAQ)
Snapshot of EV3 INC (EVVV)
|
OPEN
$16.16
|
PREVIOUS CLOSE
$16.07
|
|
|
DAY HIGH
$16.16
|
DAY LOW
$15.87
|
|
|
52 WEEK HIGH
03/8/10 - $16.27
|
52 WEEK LOW
03/19/09 - $6.62
|
|
|
MARKET CAP
1.8B
|
AVERAGE VOLUME 10 D
871.5K
|
|
|
EPS TTM
$0.48
|
SHARES OUTSTANDING
112.6M
|
|
|
EVVV Does Not Pay Dividends
|
P/E TTM
33.3x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
A fresh wave of buyouts plus earnings from Merck pushes indexes higher Monday after Friday's sell-off
Key developments for EV3 INC (EVVV)
ev3, Inc. expected to Report Q1 2010 Results on April 29, 2010. This event was calculated by Capital IQ (Created on February 18, 2010).
ev3, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company's net sales were $126,753,000 against $106,125,000 a year ago. Income from operations was $15,095,000 against loss from operations of $288,461,000 a year ago. Income before income taxes was $14,689,000 against loss before income taxes of $290,835,000 a year ago. Net income was $13,001,000 or $0.12 per basic and diluted share against net loss of $291,120,000 or $2.78 per basic and diluted share a year ago. Non-GAAP adjusted net income was $25,716,000 or $0.23 per diluted share against $7,948,000 or $0.08 per diluted share a year ago. For the year, the company's net sales were $449,072,000 against $422,128,000 a year ago. Income from operations was $24,357,000 against loss from operations of $332,089,000 a year ago. Income before income taxes was $26,094,000 against loss before income taxes of $333,806,000 a year ago. Net income was $41,917,000 or $0.38 per diluted share against net loss of $335,622,000 or $3.22 per diluted share a year ago. Non-GAAP adjusted net income was $66,834,000 or $0.61 per diluted share against $9,872,000 or $0.09 per diluted share a year ago. The company provided earnings guidance for the first quarter ended April 4, 2010 and for the year ended December 31, 2010. For the quarter, the company estimated non-GAAP adjusted net earnings per diluted share to be in the range of $0.12 and $0.15. The company expects net sales to be in the range of $115 to $118 million, an increase of 14% to 18% over the first quarter of 2009. At current rates, foreign currency exchange rate fluctuations are expected to positively impact revenue growth in the first quarter of 2010 by $1.5 to $2.0 million. For the year 2010, the company estimated non-GAAP adjusted net earnings per diluted share to be in the range of $0.78 and $0.84. The company expects net sales to be in the range of $500 to $515 million compared to $449.1 million of net sales in 2009. Net sales growth is expected to be approximately 11% to 15%.
ev3, Inc. announced that they will report Q4, 2009 results on 02/18/2010
ev3, Inc. financial resources
EVVV Competitors
| Company | Last | Change |
| Angiodynamics Inc | $15.10 USD | -0.44 |
| Integra LifeSciences Holdings Corp | $41.96 USD | +0.03 |
| Micrus Endovascular Corp | $20.41 USD | -0.19 |
| Spectranetics Corp | $7.36 USD | -0.11 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | EVVV | Industry Range |
| Price/Earnings | 41.6x |
|
| Price/Sales | 3.9x |
|
| Price/Book | 2.4x |
|
| Price/Cash Flow | 26.9x |
|
| TEV/Sales | 3.8x |
|
|
EVVV |
||
EVVV transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About ev3, Inc.
ev3 Reports 2009 Fourth Quarter and Full-Year Financial Results and 2010 Guidance
Read article
ev3 Reports 2009 Fourth Quarter and Full-Year Financial Results and 2010 Guidance
Read article
ev3 Announces Promotion of Two Senior Executives
Read article
ev3 Announces Promotion of Two Senior Executives
Read article
ev3, Inc. Q3 2009 Earnings Call Transcript
Read article